WO2018202910A1 - Combinaison d'un antibiotique et d'un inhibiteur de bcl-2 et utilisations correspondantes - Google Patents

Combinaison d'un antibiotique et d'un inhibiteur de bcl-2 et utilisations correspondantes Download PDF

Info

Publication number
WO2018202910A1
WO2018202910A1 PCT/EP2018/061694 EP2018061694W WO2018202910A1 WO 2018202910 A1 WO2018202910 A1 WO 2018202910A1 EP 2018061694 W EP2018061694 W EP 2018061694W WO 2018202910 A1 WO2018202910 A1 WO 2018202910A1
Authority
WO
WIPO (PCT)
Prior art keywords
combination
bcl
mitochondrially
inhibitor
tigecycline
Prior art date
Application number
PCT/EP2018/061694
Other languages
English (en)
Inventor
Micol RAVA'
Aleco D'ANDREA
Bruno Amati
Original Assignee
Fondazione Istituto Italiano Di Tecnologia
Ieo-Istituto Europeo Di Oncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Istituto Italiano Di Tecnologia, Ieo-Istituto Europeo Di Oncologia filed Critical Fondazione Istituto Italiano Di Tecnologia
Publication of WO2018202910A1 publication Critical patent/WO2018202910A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

La présente invention concerne l'utilisation thérapeutique d'une combinaison d'au moins un antibiotique ciblant les mitochondries et d'au moins un inhibiteur de BCL-2 destiné à être utilisé dans le traitement des lymphomes B à double liaison MYC/BCL2, ainsi que des compositions associées.
PCT/EP2018/061694 2017-05-05 2018-05-07 Combinaison d'un antibiotique et d'un inhibiteur de bcl-2 et utilisations correspondantes WO2018202910A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17169829.3 2017-05-05
EP17169829 2017-05-05
EP18154368.7 2018-01-31
EP18154368 2018-01-31

Publications (1)

Publication Number Publication Date
WO2018202910A1 true WO2018202910A1 (fr) 2018-11-08

Family

ID=62116883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/061694 WO2018202910A1 (fr) 2017-05-05 2018-05-07 Combinaison d'un antibiotique et d'un inhibiteur de bcl-2 et utilisations correspondantes

Country Status (1)

Country Link
WO (1) WO2018202910A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160821B2 (en) 2017-05-19 2021-11-02 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
US11667639B2 (en) 2017-06-26 2023-06-06 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149492A1 (fr) 2010-05-26 2011-12-01 Abbott Laboratories Agents induisant l'apoptose pour le traitement du cancer et de maladies immunes et auto-immunes
WO2015130585A1 (fr) * 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Méthode de traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149492A1 (fr) 2010-05-26 2011-12-01 Abbott Laboratories Agents induisant l'apoptose pour le traitement du cancer et de maladies immunes et auto-immunes
WO2015130585A1 (fr) * 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Méthode de traitement du cancer

Non-Patent Citations (82)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs", 1985, ELSEVIER
"Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
A. D. SCHIMMER; M. SKRTIC, EXPERT REV HEMATOL, vol. 5, 2012, pages 117 - 119
A. D'ANDREA ET AL., ONCOTARGET, vol. 7, 2016, pages 72415 - 72430
A. FANIDI ET AL., NATURE, vol. 359, 1992, pages 554 - 556
A. IANEVSKI ET AL., BIOINFORMATICS, vol. 33, 2017, pages 2413 - 2415
A. J. SOUERS ET AL., NAT MED, vol. 19, 2013, pages 202 - 208
A. M. KROON ET AL., CANCER LETT, vol. 25, 1984, pages 33 - 40
A. R. DELBRIDGE ET AL., NATURE REVIEWS. CANCER, vol. 16, 2016, pages 99 - 109
A. R. ORAN ET AL., ONCOTARGET, vol. 7, 2016, pages 72395 - 72414
A. REDDY ET AL., CELL, vol. 171, 2017, pages 481 - 494
A. SABO ET AL., NATURE, vol. 511, 2014, pages 488 - 492
A. STRASSER ET AL., NATURE, vol. 348, 1990, pages 331 - 333
A. VIALE ET AL., NATURE, vol. 514, 2014, pages 628 - 632
A. W. ROBERTS, RINSHO KETSUEKI, vol. 57, 2016, pages 2054 - 2058
A. YOUNES ET AL., NAT REV CLIN ONCOL, vol. 14, 2017, pages 335 - 346
AGNELLO ET AL., CYTOTECHNOLOGY, vol. 56, no. 3, March 2008 (2008-03-01), pages 145 - 9
ALECO D'ANDREA ET AL: "The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas", ONCOTARGET, 1 January 2016 (2016-01-01), United States, pages 72415, XP055491948, Retrieved from the Internet <URL:www.impactjournals.com/oncotarget> DOI: 10.18632/oncotarget.11719 *
B. OZSVARI ET AL., ONCOTARGET, vol. 8, 2017, pages 67457 - 67472
B. WANG ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 490, 2017, pages 767 - 773
B. Z. CARTER ET AL., SCI TRANSL MED, vol. 8, 2016, pages 355ral 17
BERG ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
C. BILLARD, MOL. CANCER THER., vol. 9, 2013, pages 1691 - 700
C. I. KOSMIDIS; P. H. CHANDRASEKAR, LEUK LYMPHOMA, vol. 53, 2012, pages 8 - 18
C. SARKOZY ET AL., LANCET ONCOL, vol. 16, 2015, pages e555 - 567
C. TANG ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 446, 2014, pages 105 - 112
C. VAN DEN BOGERT ET AL., CANCER RES, vol. 41, 1981, pages 1943 - 1947
C. VAN DEN BOGERT ET AL., CANCER RES, vol. 46, 1986, pages 3283 - 3289
C. VAN DEN BOGERT ET AL., LEUK RES, vol. 9, 1985, pages 617 - 623
D. J. LANDSBURG ET AL., J CLIN ONCOL, 2017
D. L. VAUX ET AL., NATURE, vol. 335, 1988, pages 440 - 442
D'ANDREA ET AL., ONCOTARGET, vol. 7, no. 45, 8 November 2016 (2016-11-08), pages 72415 - 72430
E. C. TOWNSEND ET AL., CANCER CELL, vol. 29, 2016, pages 574 - 586
E. D. LAGADINOU ET AL., CELL STEM CELL, vol. 12, 2013, pages 329 - 341
E. M. KUNTZ ET AL., NAT MED, vol. 23, 2017, pages 1234 - 1240
E. NORBERG ET AL., CELL DEATH DIFFER, vol. 24, 2017, pages 251 - 262
E.L. ELIEL; S.H. WILEN: "Stereochemistry of Carbon Compounds", 1994, JOHN WILEY & SONS, pages: 1119 - 1190
G. A. REED ET AL., CANCER MED, vol. 5, 2016, pages 3031 - 3040
G. BUCANEVE ET AL., J CLIN ONCOL, vol. 32, 2014, pages 1463 - 1471
G. P. DIMRI ET AL., PROC NATL ACAD SCI USA, vol. 92, 1995, pages 9363 - 9367
G. WRIGHT ET AL., PROC NATL ACAD SCI USA, vol. 100, 2003, pages 9991 - 9996
H. G. DREXLER ET AL., LEUK LYMPHOMA, vol. 57, 2016, pages 1015 - 1020
H. LI ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 467, 2015, pages 14 - 20
J. D. LEVERSON ET AL., CANCER DISCOV, 16 November 2017 (2017-11-16)
J. F. SEYMOUR ET AL., LANCET ONCOL, vol. 18, 2017, pages 230 - 240
J. R. DORR ET AL., NATURE, vol. 501, 2013, pages 421 - 425
J. TAN ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 483, 2017, pages 17 - 23
J. VELEZ ET AL., ONCOTARGET, vol. 7, 2016, pages 51435 - 51449
J. W. FRIEDBERG, BLOOD, vol. 130, 2017, pages 590 - 596
K. J. FREISE ET AL., HEMATOL ONCOL, vol. 35, 2017, pages 679 - 684
K. M. LEE ET AL., CELL METAB, vol. 26, 2017, pages 633 - 647
K. S. SCHWAB ET AL., INFECTION, vol. 42, 2014, pages 97 - 104
K. V. ROLSTON ET AL., INT JANTIMICROB AGENTS, vol. 49, 2017, pages 416 - 421
M. A. ANDERSON ET AL., THER ADV HEMATOL, vol. 7, 2016, pages 52 - 64
M. CINAR ET AL: "Co-inhibition of MYC and BCL2 signaling is a potentially effective strategy for treatment of double hit and triple hit B-cell lymphoma", GUT, vol. 63, 1 October 2014 (2014-10-01), UK, pages 456A, XP055492303, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2013-306219 *
M. M. JENSEN ET AL., BMC MED IMAGING, vol. 8, 2008, pages 16
M. S. DAVIDS ET AL., J CLIN ONCOL, vol. 35, 2017, pages 826 - 833
M. SKRTIC ET AL., CANCER CELL, vol. 20, 2011, pages 674 - 688
N. MASIR ET AL., PATHOLOGY, vol. 42, 2010, pages 212 - 216
NANA SASAKI ET AL: "Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrentBcl-2 and c-Myc overexpression", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 39, no. 8, 2 May 2011 (2011-05-02), pages 817 - 828.e1, XP028276803, ISSN: 0301-472X, [retrieved on 20110511], DOI: 10.1016/J.EXPHEM.2011.05.002 *
P. SESQUES; N. A. JOHNSON, BLOOD, vol. 129, 2017, pages 280 - 288
R. A. JONES ET AL., J CLIN INVEST, vol. 126, 2016, pages 3739 - 3757
R. F. CHEMALY ET AL., MEDICINE (BALTIMORE, vol. 88, 2009, pages 211 - 220
R. LAMB ET AL., ONCOTARGET, vol. 6, 2015, pages 4569 - 4584
R. P. BISSONNETTE ET AL., NATURE, vol. 359, 1992, pages 552 - 554
S. ACKLER ET AL: "ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo", MOLECULAR CANCER THERAPEUTICS, vol. 7, no. 10, 1 October 2008 (2008-10-01), US, pages 3265 - 3274, XP055492267, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-08-0268 *
S. CANG ET AL., J HEMATOL ONCOL, vol. 8, 2015, pages 129
S. CANG ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 8, 2015, pages 129
S. H. SWERDLOW ET AL., BLOOD, vol. 127, 2016, pages 2375 - 2390
S. MONTI ET AL., BLOOD, vol. 105, 2005, pages 1851 - 1861
S. STILGENBAUER ET AL., LANCET ONCOL, vol. 17, 2016, pages 768 - 778
SASARMAN F ET AL., METHODS MOL BIOL, vol. 837, 2012, pages 207 - 17
SKRTIC M ET AL., CANCER CELL, vol. 20, no. 5, 15 November 2011 (2011-11-15), pages 674 - 88
T. K. KO ET AL., ONCOTARGET, vol. 5, 2014, pages 9033 - 9038
TSE, CANCER RESEARCH, vol. 68, no. 9, 2008, pages 3421
V.R. SUTTON; D.L. VAUX; J.A. TRAPANI, J. OF IMMUNOLOGY, vol. 158, no. 12, 1997, pages 5783
X. JIA ET AL., FUNDAM CLIN PHARMACOL, vol. 30, 2016, pages 297 - 306
X. ZHONG ET AL., TUMOUR BIOL, vol. 37, 2016, pages 7615 - 7623
Y. JITKOVA ET AL., PLOS ONE, vol. 9, 2014, pages e95281
Y. KHELFA ET AL., CURR ONCOL REP, vol. 19, 2017, pages 74
Z. LU ET AL., JEXP CLIN CANCER RES, vol. 36, 2017, pages 43
Z. XU ET AL., FRONT PHARMACOL, vol. 7, 2016, pages 473

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
US11865124B2 (en) 2017-04-21 2024-01-09 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCS)
US11160821B2 (en) 2017-05-19 2021-11-02 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11865130B2 (en) 2017-05-19 2024-01-09 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11667639B2 (en) 2017-06-26 2023-06-06 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
US11667640B2 (en) 2017-06-26 2023-06-06 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Similar Documents

Publication Publication Date Title
JP6423425B2 (ja) 結晶性ブロモドメインインヒビター
ES2523999T3 (es) Dispersiones sólidas que contienen inhibidores de cinasas
RU2550134C2 (ru) Твердые дисперсии, содержащие способствующее апоптозу
CA2929347A1 (fr) Composes de benzamide sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy) (hetero)aryle substitue et leur utilisation comme agents induisant l&#39;apoptose pour le traitement de cancer et demaladies immunes et autoimmunes
KR102124715B1 (ko) 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물
MX2011013797A (es) Suspension de farmaco estable de nanoparticula.
WO2018202910A1 (fr) Combinaison d&#39;un antibiotique et d&#39;un inhibiteur de bcl-2 et utilisations correspondantes
ES2559212T3 (es) Formas cristalinas de inhibidores de cinasas
TWI492949B (zh) 結晶型激酶抑制劑
US8940759B2 (en) Crystalline forms of kinase inhibitors
CN114853753B (zh) 吡啶并[1,2-a]嘧啶酮类似物及其在制备FGFR抑制剂中的用途
US20150126545A1 (en) Compositions containing kinase inhibitors
US20170197980A1 (en) N-(4-phenyl)-n&#39;-(3-fluorophenyl)urea docusate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18722988

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18722988

Country of ref document: EP

Kind code of ref document: A1